Everist Genomics, a developer of gene-based molecular assays, is planning to introduce its CardioDefender diagnostic system.

CardioDefender is a real-time, mobile, ECG System features patented analytical smartphone software with a Bluetooth device and electrodes.

The electrodes, which are attached to the patient’s skin delivers beat-by-beat, and quantitative heart rhythm data to the Bluetooth device, which then transmits the data to the smartphone.

The smartphone software analyzes the heart rhythm and sends data to a cardiac monitoring center which maintains an encrypted record of the data which can be reviewed by physicians.

CardioDefender system automatically transmits an alert to the patient’s physician while the event of arrhythmia is occurring.

CardioDefender system has received the US Food and Drug Administration (FDA) and CE mark approval.